Portrazza FDA Approval History
FDA Approved: Yes (First approved November 24, 2015)
Brand name: Portrazza
Generic name: necitumumab
Dosage form: Injection
Company: Eli Lilly and Company
Treatment for: Non Small Cell Lung Cancer
Portrazza (necitumumab) is an epidermal growth factor receptor (EGFR) antagonist indicated in combination with gemcitabine and cisplatin for the treatment of patients with metastatic squamous non-small cell lung cancer.
Development timeline for Portrazza
| Date | Article |
|---|---|
| Nov 24, 2015 | Approval FDA Approves Portrazza (necitumumab) for Advanced Squamous Non-Small Cell Lung Cancer |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
